Company

Over the next two decades (hence our name: 2020) the healthcare industry will continue to undergo a transformation catalyzed by developments in 'Personalized Medicine'.

At 20/20, we have assembled a group of experts with a diverse range of backgrounds who have developed a vision for healthcare in the year 2020. This vision guides our strategy for developing and commercializing technologies that we feel will accelerate the implementation of successful 'Personalized Medicine' approaches.

Our team approach relies on an efficient and strategic use of time and resources, to bring our portfolio companies' products to market. We continually assess both technologies and the health care market to determine which of the innovations that we evaluate fit with the 2020 vision.

Once a 'good fit' is determined, we allocate resources to the project. These resources include capital, management and technical expertise in addition to investing significant funds in each project.

20/20HCP has a unique focus on diagnostic imaging and image enhancement and the evolution of diagnostic imaging and personalized medicine. Our mission is to rapidly deliver medical breakthroughs to patients by providing the companies responsible for these developments with the resources necessary to realize their vision.

Strategy

20/20HCP employs a flexible structure to address market opportunities, with a strong focus on markets where our experience, knowledge, and network can build companies' value within the Health Care industry. Each project is staffed by an expert in the specific field, in addition to 20/20HCPs' partners and staff.

20/20HCP reviews various types of investment opportunities from initial pre-seed funding and newly established companies up through mature companies. Our flexible structure permits us to initiate an intensive due diligence process which can result in a fast and efficient investment round.

Projects may be structured as:

20/20HCP Direct Investments
20/20HCP lead investments, working with private investors and hedge funds, to execute larger transactions.
Assistance with strategic alliances and company mergers
Sourcing of growth capital
Board of Director level advice and other strategic consulting.

20/20HCP invests in cohesive goal oriented management teams. With the belief that a successful company must rely on excellent working relations between the investors and the management, 20/20HCP creates a close working relationships with the management team including the founder / entrepreneur, ensuring trust, honesty and earnings.

Objective

Assist fast growth companies in building value leading to a potential realization.

Serve as a linkage between our portfolio and the market.

Answer the financial gap that pre-seed companies experience in the healthcare industry.

Industry info:

In recent years the approval process for venture capital equity investment has become longer and tougher stranding many early stage companies out of the investment cycle. Moreover, as venture capital funds have grown, their minimum investment requirements often dictate an inappropriate business plan in order to justify the minimum investment amount. Accordingly, the average 'time to liquidity' for an acquired start-up company in 2005 was 5.4 years. That compares with 2.4 years in 2004.

Role

Establish a structure and strategic partnerships for the early Identification of opportunities

Accelerate the convergence of medical device technologies in the Diagnostic (Dx), Therapeutic (Tx), and Prediction (Px) applications with a focus on a range of projects that are driven by a few simple assumptions:

The need for better imaging resolution while reducing exposure to radiation and other hazards will require improved contrast media and improved imaging software.
Medical Device manufacturers can no longer focus only on mechanical/electronic solutions.
Proprietary biomathematics technologies will become one of the principal competitive drivers for the drug development industry.
Expedite development through nimble management and short product development cycle